Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.

PURPOSE The accurate prediction of pathological stage of prostate cancer using preoperative factors is a critical aspect of treatment. In 1997 Partin et al published tables predicting pathological stage using clinical stage, Gleason score and prostate specific antigen (PSA). We tested the validity of the Partin tables. MATERIALS AND METHODS From 1990 to 1996 inclusively 5,780 patients underwent bilateral pelvic lymphadenectomy and radical prostatectomy for prostate cancer at the Mayo Clinic. However, only 2,475 of these patients met all inclusion criteria of no preoperative treatment, known biopsy Gleason score, available preoperative PSA done either before biopsy or more than 28 days after biopsy and clinical stage T1, T2 or T3a. Among the 2,475 patients 15 had positive lymph nodes and planned prostatectomy was abandoned. The receiver operating characteristics (ROC) curve area, observed and predicted Partin rates of each pathological stage, and positive and negative predictive values were used to compare the Mayo study to the Partin tables. RESULTS The distribution of pathological stage was organ confined in 67% of Mayo cases versus 48% in the Partin study, extracapsular without seminal vesicle or node involvement in 18% versus 40%, seminal vesicle involvement without nodes in 9% versus 7% and were positive nodes in 6% versus 5%. Using the predicted probabilities of Partin et al the ROC curve area for predicted node positive disease was 0.84 for Mayo cases compared to an estimated 0. 82 in the Partin series. The ROC curve area for predicting organ confined cancer was 0.76 for the Mayo Clinic compared to an estimated 0.73 for the Partin series. The observed rates of node positive disease were similar to those predicted (Partin) based on clinical stage, PSA and Gleason score. For organ confined disease Mayo rates were consistently higher than those predicted from the Partin series using a cut point of 0.50 or greater. Positive and negative predictive values were 0.83 and 0.49 versus 0.63 and 0.70 for the Mayo Clinic and Partin series. CONCLUSIONS Our study provides strong evidence that sensitivity and specificity of the Partin tables for external clinical sites are similar to what was reported.

[1]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[2]  D. Bostwick,et al.  The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. , 1995, The Journal of urology.

[3]  E D Crawford,et al.  Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. , 1996, Urology.

[4]  P. Humphrey,et al.  Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues , 1995 .

[5]  P. Carroll,et al.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.

[6]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[7]  T. Wheeler,et al.  Workgroup 2: Staging and reporting of prostate cancer‐‐Sampling of the radical prostatectomy specimen , 1996, Cancer.

[8]  A. D'Amico,et al.  The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer , 1995 .

[9]  N. Olson,et al.  Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. , 1993, The Journal of urology.

[10]  D. Bostwick,et al.  The definition and preoperative prediction of clinically insignificant prostate cancer. , 1996, JAMA.

[11]  M W Kattan,et al.  Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma , 1997, Cancer.

[12]  D. Bostwick,et al.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.

[13]  A. Tewari,et al.  The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. , 1995, Urology.

[14]  J. Oesterling,et al.  Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. , 1987, The Journal of urology.

[15]  M W Kattan,et al.  Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. , 1996, The Journal of urology.

[16]  J. Oesterling,et al.  Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. , 1993, Urology.

[17]  D C Young,et al.  An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. , 1996, The Journal of urology.

[18]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[19]  T. Therneau,et al.  Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. , 1989, The Journal of urology.

[20]  R. B. Smith,et al.  Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. , 1992, The Journal of urology.

[21]  D. Paulson.  Impact of radical prostatectomy in the management of clinically localized disease. , 1994, The Journal of urology.

[22]  T. Stamey,et al.  Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. , 1995, Urology.

[23]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[24]  M. Kattan,et al.  The role of digital rectal examination, biopsy Gleason sum and prostate-specific antigen in selecting patients who require pelvic lymph node dissections for prostate cancer. , 1996, British journal of urology.

[25]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.